Abstract
•Epithelial ovarian cancer is a constellation of diseases challenging development.•Patient classification systems should incorporate multiple descriptive factors.•New platforms for drug development (e.g. neoadjuvant chemotherapy) are encouraged.•Patient advocate collaborators are vital to meeting the many challenges of enrollment.•Surrogate endpoints (e.g. PFS and response) are viable for accelerated approval.